Key Takeaways
- Alan closed €480M Series G led by Prosus at €5.5B valuation, making it one of Europe's most valuable healthtech companies
- The company hit €800M ARR in Q1 2026 with 53% year-over-year growth and is profitable in France
- Prosus will help Alan expand internationally and integrate its AI capabilities including its Large Commerce Model
French digital health insurer Alan has raised €480 million in a Series G round led by Prosus, the Dutch tech investment giant, pushing the company's valuation to €5.5 billion. The deal marks one of the largest European healthtech rounds this year and signals continued investor appetite for AI-driven healthcare platforms.
Existing backers Index Ventures and Teachers' Venture Growth participated alongside new investor Dara Holdings. The round remains subject to regulatory approvals.
Alan reported more than €800 million in annual recurring revenue in Q1 2026, up 53% year-over-year. The company now serves over 1.1 million people and has reached profitability in France, its home market and largest operation.
What does Alan actually do?
Founded in 2016 by Jean-Charles Samuelian-Werve and Charles Gorintin, Alan started as France's first independent health insurance company licensed in over three decades. The founders set out to disrupt the traditional French mutuelle market, which had stagnated while customers put up with clunky processes and poor digital experiences.
The company has since evolved beyond insurance into a broader healthcare platform combining coverage, care delivery, and preventive services. It offers telemedicine, mental health support, and wellness tools alongside its core insurance products.
Alan describes itself as "AI-native," claiming this approach lets it personalize healthcare while scaling without proportional headcount growth. In a sector where administrative bloat is the norm, that efficiency argument resonates with investors.
Why is Prosus leading this round?
Prosus, best known for its early stake in Tencent, has been aggressively deploying capital into companies it sees as AI transformation plays. Healthcare fits that thesis.
“Healthcare presents one of the most significant global opportunities for AI-led transformation.”
— Fahd Beg, Head of Investments at Prosus
Beyond capital, Prosus plans to offer Alan access to its AI capabilities, including something called a "Large Commerce Model." The details on that integration remain vague, but the intent is clear: accelerate product development and international expansion.
Alan currently operates in France, Spain, and Belgium. This funding should fuel entry into additional markets, though the company hasn't specified which.
What the CEO says about Alan's edge
Samuelian-Werve, who also co-founded French AI startup Mistral, posted on LinkedIn that the round "gives us the means to move faster: expand to new countries, deepen our presence where we already are, invest even more in AI and product, and pursue the strategic opportunities ahead."
In a previous interview with Sifted, he attributed Alan's success to product obsession in a sleepy industry.
“We were obsessed with rethinking every single part of the user experience in a market that did very little of this, but which is huge and has lots of needs.”
— Jean-Charles Samuelian-Werve, CEO and Co-founder of Alan
That focus on user experience differentiated Alan early. The question now is whether the same approach translates across regulatory regimes and healthcare systems that vary dramatically from France's.
Where Alan fits in European healthtech
At €5.5 billion, Alan ranks among Europe's most valuable healthtech companies, competing for that title with Doctolib and the Kry/Livi group. Unlike those pure telemedicine plays, Alan's insurance backbone gives it recurring revenue and deeper customer relationships. Users pay monthly premiums, not per-visit fees.
The 53% growth rate at €800 million ARR is genuinely impressive for a company nearing decade-old status. Most startups see growth decelerate sharply at that revenue scale. Maintaining that pace while achieving profitability in France suggests the unit economics work, at least in that market.
The company is also known internally for radical transparency, including publishing salaries among employees. Whether that culture scales internationally is another open question.
Logicity's Take
Alan's combination of insurance plus care delivery creates a flywheel most digital health startups lack: the insurer has financial incentive to keep members healthy, not just treat them when sick. If the AI claims hold up, expect aggressive international expansion and potential M&A. The Mistral connection through Samuelian-Werve also positions Alan well to access top French AI talent. The risk? Regulated insurance markets are notoriously local. What works in France may require complete rebuilds elsewhere.
Frequently Asked Questions
What is Alan's valuation after the Series G?
Alan is valued at €5.5 billion following the €480 million Series G round led by Prosus.
How much revenue does Alan generate?
Alan reported more than €800 million in annual recurring revenue in Q1 2026, representing 53% year-over-year growth.
Is Alan profitable?
Yes, Alan has reached profitability in France, its largest market. The company serves over 1.1 million people.
Who founded Alan?
Jean-Charles Samuelian-Werve and Charles Gorintin founded Alan in 2016. Samuelian-Werve also co-founded Mistral AI.
Where does Alan operate?
Alan currently operates in France, Spain, and Belgium, with plans to expand to additional international markets using the new funding.
Need Help Implementing This?
Whether you're building in healthtech, exploring AI integration, or navigating European expansion, the Logicity team tracks the strategies behind stories like Alan's. Subscribe for weekly analysis on what's working in tech.
Source: Sifted
Manaal Khan
Tech & Innovation Writer
Produced with AI assistance and reviewed by the Logicity editorial team. Learn more in our Editorial Policy.
